Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America | Zendy

Betsy E. Castro | Zendy; Maritza Berrío | Zendy; Mónica L Vargas | Zendy; Lina P Carvajal | Zendy; Lina V Millan | Zendy; Rafael Ríos | Zendy; Angie K Hernandez | Zendy; Sandra Rincón | Zendy; Paola Cubides | Zendy; Erika Forero | Zendy; An Q Dinh | Zendy; Carlos Seas | Zendy; José M. Munita | Zendy; César A. Arias | Zendy; Jinnethe Reyes | Zendy; Lorena Díaz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America

Author(s) -

Betsy E. Castro,

Maritza Berrío,

Mónica L Vargas,

Lina P Carvajal,

Lina V Millan,

Rafael Ríos,

Angie K Hernandez,

Sandra Rincón,

Paola Cubides,

Erika Forero,

An Q Dinh,

Carlos Seas,

José M. Munita,

César A. Arias,

Jinnethe Reyes,

Lorena Díaz

Publication year - 2020

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkaa221

Subject(s) - etest , vancomycin , rpob , microbiology and biotechnology , staphylococcus aureus , methicillin resistant staphylococcus aureus , population , teicoplanin , medicine , glycopeptide , biology , phenotype , antibiotics , bacteria , genetics , gene , 16s ribosomal rna , environmental health

Vancomycin is a common first-line option for MRSA infections. The heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) phenotype is associated with therapeutic failure. However, hVISA isolates are usually reported as vancomycin susceptible by routine susceptibility testing procedures.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research